A recent phase III trial demonstrated that initial therapy with an immuno-agent improves progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer, published in the Journal of Clinical Oncology (online October 2, 2017; doi:10.1200/JCO.2
MADRID (Reuters) - Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair.
NEW YORK (Reuters Health) - In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors (ICIs) are more effective and safer than conventional second-line treatment, a new systematic review from The Netherlands reports.
Specific immune cells surrounding tumors may play a crucial role in how patients with head and neck cancer respond to nivolumab immunotherapy, according to research presented at the American Association of Cancer Research annual meeting (April 1-5, 2017; Washington, DC).
Patients with cancer who receive antibiotics within a month before beginning their immunotherapy treatment may find the efficacy of their treatment reduced, according to a study that will be presented at the Genitourinary Cancers Symposium (Orlando, FL, February 18, 2017; Abstract 462).
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for Immunotherapy of Cancer 2016 meeting (November 9-13; National Harbor, MD).